Revenue Update on Arrhythmia Research Technology(NYSEMKT:HRT)

Arrhythmia Research Technology(NYSEMKT:HRT) announced the earnings results for Fiscal Year 2016 and Q4. The results came in during After-Market on Mar 22, 2017. Based on the corporate Earnings and Guidance, many Investment Banking firms balance their portfolio to Sell and Buy Stocks based on their strategy of investing in stocks.Earnings per share were $-0.11.

Arrhythmia Research Technology (HRT) made into the market gainers list on Fridays trading session with the shares advancing 4.58% or 0.1796 points. Due to strong positive momentum, the stock ended at $4.1, which is also near the day’s high of $4.1. The stock began the session at $3.95 and the volume stood at 3,090 shares. The 52-week high of the shares is $4.83 and the 52 week low is $3.47. The company has a current market capitalization of $12 M and it has 28,20,999 shares in outstanding.

Several Insider Transactions has been reported to the SEC. On May 17, 2016, Marco Benedetti (director) purchased 500 shares at $3.80 per share price.Also, On Mar 17, 2016, Salvatore Jr Emma (CEO) purchased 2,500 shares at $3.90 per share price.On Mar 17, 2016, Derek Thomas Welch (CFO) purchased 360 shares at $4.09 per share price, according to the Form-4 filing with the securities and exchange commission.

Arrhythmia Research Technology Inc. is a contract manufacturing organization (CMO). Through its wholly owned subsidiary Micron Products Inc. the Company produces medical device technologies requiring precision machining and injection molding. The Company also manufactures components devices and equipment for military law enforcement industrial and consumer product applications. It is a manufacturer and distributor of silver-plated and non-silver plated conductive resin sensors for use in the manufacture of disposable electrodes for electrocardiogram (ECG) diagnostic monitoring and related instrumentation. The Company is also a contract manufacturer of orthopedic implant components for full and partial knee replacements including femorals tibial trays and inserts with capabilities. Its plastic injection molding services are suited to consumable medical products and medical device components.

Add Comment